Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 2Meningioma 2von Hippel-Lindau Disease 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Metastatic Neuroendocrine Prostate Cancer 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Ganglioneuroma 1Ganglioneuroblastoma 1Carcinoma, Neuroendocrine 1Adenocarcinoma, Follicular 1

Interventions

Nivolumab 3Cisplatin 3atezolizumab 2Irinotecan 2Ipilimumab 2Immunoglobulin G 2Etoposide 2Disulfides 2Carboplatin 2repotrectinib 1niraparib 1gallium Ga 68 dotatate 1dostarlimab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1Temozolomide 1Specimen Handling 1Radiosurgery 1Radionuclide Imaging 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Leucovorin 1IFL protocol 1Fluorouracil 1DLL3 protein, human 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × gallium Ga 68 dotatate × 90 days × Clear all
NCT04069299 2026-03-31

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

H. Lee Moffitt Cancer Center and Research Institute

Completed
30 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡